Abbott LaboratoriesABTNYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -6.37% |
| Q3 2025 | 7.24% |
| Q2 2025 | 4.13% |
| Q1 2025 | -3.43% |
| Q4 2024 | 2.10% |
| Q3 2024 | 2.30% |
| Q2 2024 | 2.05% |
| Q1 2024 | -1.01% |
| Q4 2023 | 4.39% |
| Q3 2023 | -6.90% |
| Q2 2023 | 8.56% |
| Q1 2023 | -5.35% |
| Q4 2022 | -11.41% |
| Q3 2022 | 14.04% |
| Q2 2022 | -1.87% |
| Q1 2022 | -8.05% |
| Q4 2021 | 12.80% |
| Q3 2021 | 2.75% |
| Q2 2021 | 0.00% |
| Q1 2021 | -6.30% |
| Q4 2020 | 20.34% |
| Q3 2020 | 2.84% |
| Q2 2020 | -2.08% |
| Q1 2020 | 0.17% |
| Q4 2019 | -3.20% |
| Q3 2019 | 2.95% |
| Q2 2019 | -13.88% |
| Q1 2019 | 19.43% |
| Q4 2018 | -2.09% |
| Q3 2018 | 0.00% |
| Q2 2018 | -1.38% |
| Q1 2018 | -5.99% |
| Q4 2017 | 25.35% |
| Q3 2017 | -5.19% |
| Q2 2017 | -3.88% |
| Q1 2017 | 60.06% |
| Q4 2016 | 0.60% |
| Q3 2016 | -3.45% |
| Q2 2016 | -8.18% |
| Q1 2016 | 2.71% |